PMID- 37566876
OWN - NLM
STAT- MEDLINE
DCOM- 20240422
LR  - 20240425
IS  - 1538-7151 (Electronic)
IS  - 0277-1691 (Print)
IS  - 0277-1691 (Linking)
VI  - 43
IP  - 3
DP  - 2024 May 1
TI  - Comprehensive Immunohistochemical Analysis of Mesonephric Marker Expression in 
      Low-grade Endometrial Endometrioid Carcinoma.
PG  - 221-232
LID - 10.1097/PGP.0000000000000976 [doi]
AB  - Immunohistochemical markers shown to be useful in identifying/confirming 
      mesonephric/mesonephric-like differentiation (MLD markers) include thyroid 
      transcription factor (TTF1), GATA-binding protein 3 (GATA3), and cluster of 
      differentiation 10 (CD10). Only a few studies have examined the expression levels 
      of MLD markers in endometrial endometrioid carcinomas (EECs). This study aimed to 
      analyze the frequency and pattern of MLD marker expression in low-grade EECs. We 
      performed immunostaining for the detection of TTF1, GATA3, and CD10 expression in 
      50 low-grade EEC tissue samples and evaluated their staining proportion and 
      intensity. Nine tumors (18.0%) expressed at least one MLD marker in varying 
      proportions and intensities, and 2 of these tumors were positive for 2 MLD 
      markers (TTF1/GATA3 and GATA3/CD10, respectively). Three (6.0%) tumors showed 
      moderate-to-strong nuclear TTF1 immunoreactivity in </=5% of the tumor cells. Five 
      tumors (10.0%) had at least moderate nuclear GATA3 staining, and three of them 
      displayed a staining proportion of >/=15%. Three tumors (6.0%) were focal (mean 
      proportion, 15%) but strongly positive for CD10. Our findings indicate that a 
      subset of EEC can express one or more MLD markers with varying staining 
      proportions and intensities. Given that a diagnosis of uterine mesonephric-like 
      adenocarcinoma should be established based on a combination of characteristic 
      histologic features, unique immunophenotypes, and confirmed molecular findings, 
      pathologists should not exclude EEC based only on the presence of focal 
      immunoreactivity for MLD markers. Awareness of the atypical expression patterns 
      of MLD markers in EEC helps pathologists avoid misdiagnosing EEC as a uterine 
      mesonephric-like adenocarcinoma.
CI  - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Lee, Yurimi
AU  - Lee Y
AD  - Department of Pathology and Translational Genomics, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Republic of Korea (Y.L., S.C., 
      H.-S.K.).
FAU - Choi, Sangjoon
AU  - Choi S
FAU - Kim, Hyun-Soo
AU  - Kim HS
LA  - eng
PT  - Journal Article
DEP - 20230811
PL  - United States
TA  - Int J Gynecol Pathol
JT  - International journal of gynecological pathology : official journal of the 
      International Society of Gynecological Pathologists
JID - 8214845
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Female
MH  - Humans
MH  - *Carcinoma, Endometrioid/pathology
MH  - Mesonephros/pathology
MH  - Uterus/pathology
MH  - *Adenocarcinoma/pathology
MH  - Biomarkers, Tumor/metabolism
MH  - *Endometrial Neoplasms/metabolism
PMC - PMC11022992
COIS- The authors declare no conflict of interest.
EDAT- 2023/08/11 18:42
MHDA- 2024/04/22 06:43
PMCR- 2024/04/17
CRDT- 2023/08/11 16:52
PHST- 2024/04/22 06:43 [medline]
PHST- 2023/08/11 18:42 [pubmed]
PHST- 2023/08/11 16:52 [entrez]
PHST- 2024/04/17 00:00 [pmc-release]
AID - 00004347-990000000-00100 [pii]
AID - IJGP22-5228 [pii]
AID - 10.1097/PGP.0000000000000976 [doi]
PST - ppublish
SO  - Int J Gynecol Pathol. 2024 May 1;43(3):221-232. doi: 
      10.1097/PGP.0000000000000976. Epub 2023 Aug 11.